Justices Turn Away Merck's Bone Drug Warning Label Row
By Ryan Harroff and Carla Baranauckas · June 16, 2025, 10:07 AM EDT
The U.S. Supreme Court on Monday rejected Merck Sharp & Dohme Corp.'s request to review a Third Circuit decision that more than 1,000 failure-to-warn claims over its osteoporosis drug Fosamax can...
To view the full article, register now.